Prophylix Pharma As

Prophylix Pharma As Prophylix is a company developing a new prophylactic drug to prevent newborns from suffering from foetal and neonatal alloimmune thrombocytopenia (FNAIT).

Prophylix Pharma AS (PPAS) is a Norwegian biotech company developing a new prophylactic medicinal product to prevent newborns from foetal and neonatal alloimmune thrombocytopenia (FNAIT). FNAIT is a condition that can lead to severe brain damage and death. The medicinal product is specific IgG antibodies made from plasma of rare donors recruited from blood banks in several European countries. Prophylix is the Coordinator of the EU funded PROFNAIT project which aims at developing a prophylactic treatment of FNAIT

Se nyhetssak i Dagens Medisin (Norwegian only)
02/10/2014

Se nyhetssak i Dagens Medisin (Norwegian only)

Klarsignal i USA for forenklet utviklingsløp for en norskutviklet vaksine mot livstruende tilstand.

Adresse

Tromsø
9019

Telefon

+4746777368

Nettsted

Varslinger

Vær den første som vet og la oss sende deg en e-post når Prophylix Pharma As legger inn nyheter og kampanjer. Din e-postadresse vil ikke bli brukt til noe annet formål, og du kan når som helst melde deg av.

Kontakt Praksisen

Send en melding til Prophylix Pharma As:

Snarveier

Del

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Type